Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Focus-out-Brille zur Emmetropisierung bei chinesischen Kindern

17. November 2026 aktualisiert von: Children's Hospital of Fudan University

Wirkung einer peripheren Focus-out-Brille auf die Emmetropisierung bei chinesischen Kindern im Alter von 6-8 Jahren: 2 Jahre Randomisierte klinische Studie.

The purpose of this study is to characterize the effects of peripheral focous-out glasses on emmetropization in non-myopic Chinese Children Aged 6-8 Years.This is a prospective, parallel-controlled randomized trial.

Studienübersicht

Detaillierte Beschreibung

Myopia is one of the most common eye diseases that cause visual impairment and blindness, and the high rate of myopia in young people is a major public health issue. Based on the clinical studies of optical defocusing to regulate eye growth and refractive changes through visual signal feedback, we hypothesize that early wearing of peripheral defocus glasses in children can slow down the process of emmetropization and even prevent the onset of myopia by producing more myopic defocusing. The aim of this study is to investigate whether wearing peripheral defocus glasses can effectively delay emmetropization in non-myopic children aged 6-8 years , and to further explore its effect on preventing the onset of myopia.

The study adopts a 2-year,single-centre, randomized, parallel-controlled trial with a non-blinded design. Subjects who pass the screening period will have their baseline data collected and will be assigned to the experimental or control groups according to the randomization principle. The experimental group will be fitted with Direct Emmetropia with Focus-out Glasses (hereafter referred to as DEFOG) to guide the emmetropization process. The control group will be given no treatment and will be a blank control. Baseline data including visual acuity, cycloplegic objective refraction, axis length, accommodation amplitude, strabismus examination, pupil size, choroidal thickness and peripheral retinal refraction will be measured when enrolled in the group and follow-up data will be measured at month 6, 12, 18 and 24. The primary interest of this study will be studied by comparing the difference in cycloplegic objective refraction changes between month 24 and baseline in the two groups of subjects.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

160

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 201110
        • Children's Hospital of Fudan University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Jahre bis 8 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Age: ≥6 and ≤8 years at enrollment.
  2. At least one parent' s Spherical equivalent refraction≤-3.00D.
  3. Spherical equivalent refractions (SERs) under cycloplegia: +0.50 to +1.50 diopters (D)
  4. Astigmatism ≤1.00 D .
  5. Anisometropia ≤1.00 D.
  6. Best Corrected Visual Acuity (BCVA) : 1.0 or better
  7. Provision of consent written by subject's legal guardian
  8. Willing and able to participate in all required activities of the study

Exclusion Criteria:

  1. Any of the following abnormalities on the ocular surface, such as trachoma, pemphigoid, chemical injury, heat burn, radiation injury, etc.
  2. Eyelid abnormalities (e.g. entropion, ectropion, tumor, edema, blepharospasm, incomplete eyelid closure, severe trichiasis, severe ptosis) ,which affect eyelid function in either eye
  3. Eye diseases such as strabismus, amblyopia, anisometropia, fundus diseases, and accommodation abnormality,etc.
  4. Prior treatment of myopia control in either eye, including but not limited to drugs, orthokeratology, low-level red-light therapy, etc.
  5. Noncompliance with measurement at enrollment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: DEFOG group

Subjescts will wear DEFOG glasses(peripheral focus-out glasses).

Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.

Kein Eingriff: Control group

Subjects in the control group will just be observed.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Changes of Cycloplegic Objective Refraction(spherical equivalent refraction, SER)(D)
Zeitfenster: From baseline till the 24th month

Changes of cycloplegic objective refraction(i.e reflected by SER) from baseline till the 24th month (only the right-eye data included). Objective refraction data will be examined by AUTO REF/KERATOMETER. Ciliary muscle paralysis will be performed by using 1% cyclopentanone eye drops, 2 doses in each eye, 2 doses 5 minutes apart. The optometry will be performed after 20 minutes of complete ciliary muscle paralysis (disappearance of pupil response to light or pupil diameter at least greater than 6 mm). SER is calculated by adding the sum of the sphere power with half of the cylinder power. Baseline data will be measured at the time of enrollment. Follow-up data will be measured on the 24th month from baseline. The 24th month data will be subtracted from the baseline data to obtain changes.

From baseline till the 24th month

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes of Cycloplegic Objective Refraction(SER) (D)
Zeitfenster: The 6th month, the 12th month and the 18th month from baseline

Changes of cycloplegic objective refraction (i.e reflected by SER) different follow-up time and the baseline time (only the right-eye data included). Objective refraction data will be examined by AUTO REF/KERATOMETER.

The 6th month, the 12th month and the 18th month from baseline
Myopia
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Cycloplegic SER≦-0.50D at any follow-up time. Objective refraction data will be examined by AUTO REF/KERATOMETER.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Changes of Axial Length(AL)(mm)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Changes of Axial Length (AL) between different follow-up time and the baseline time (only the right-eye data included).AL will be examined by IOL Master.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Amplitude of Accommodation (AMP)(D)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Amplitude of Accommodation (AMP) at any follow-up time (only the right-eye data included). AMP will be examined by lens test.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Uncorrected Visual Acuity
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

The Logarithmic Visual Acuity at any follow-up time (only the right-eye data included).

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Strabismus Examination(△)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Strabismus examination at any follow-up time by SYNOPTOPHORE.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Changes of Choroidal Thickness (ChT) (um)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Changes of Choroidal Thickness (ChT)between different follow-up time and the baseline time (only the right-eye data included). ChT will be examined by OPTICALCOHERENCETOMOGRAPHY.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Pupil size(mm)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Pupil size at any follow-up time (only the right-eye data included).

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Peripheral Retinal Refraction(D)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Peripheral Retinal Refraction at any follow-up time (only the right-eye data included). Peripheral Retinal Refraction will be examined by AUTO FUNDUS CAMERA.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
The percentage of participants with fast myopic shift
Zeitfenster: From baseline till the 24th month

The percentage of participants with fast myopic shift over 2 years(only the right-eye data included). The fast myopic shift is defined as cycloplegic objective refraction (i.e reflected by SER) myopic shift of at least 1.00 D. Objective refraction data will be examined by AUTO REF/KERATOMETER.

From baseline till the 24th month
Corneal curvature(D) or radius of curvature(mm)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

Corneal curvature or radius of curvature(only the right-eye included). They can be interconverted. Data will be examined by AUTO REF/KERATOMETER.

The 6th month, the 12th month, the 18th month and the 24th month from baseline
Astigmatism (D)
Zeitfenster: The 6th month, the 12th month, the 18th month and the 24th month from baseline

The adtigmatism at any follow-up time (only the right-eye data included).

The 6th month, the 12th month, the 18th month and the 24th month from baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. März 2023

Primärer Abschluss (Tatsächlich)

2. April 2026

Studienabschluss (Tatsächlich)

2. April 2026

Studienanmeldedaten

Zuerst eingereicht

10. Januar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Januar 2023

Zuerst gepostet (Tatsächlich)

19. Januar 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • DEFOG

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren